Traumatic brain injury (TBI) is the leading cause of death and disability in young adults in the developed world, each year causing approximately two million emergency room visits, 52,000 d
Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, tells us how Neurosoft's electrode implant aims to reduce inflammation and scar tissue for patients, provide higher quality brain recor
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio